SOLICITATION NOTICE
Q -- DNA methylation at chromosome 8q24 and prostate cancer risk
- Notice Date
- 7/12/2014
- Notice Type
- Presolicitation
- NAICS
- 493110
— General Warehousing and Storage
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP42581-83
- Archive Date
- 8/12/2014
- Point of Contact
- Gwennifer K. Epps, Phone: 240-276-5445, Terry Galloway, Phone: 240-276-5384
- E-Mail Address
-
eppsg@mail.nih.gov, gallowaytl@mail.nih.gov
(eppsg@mail.nih.gov, gallowaytl@mail.nih.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis 10 pyrosequencing assays and 8 plates/assay (~736 samples, including QC samples) from EpigenDx Inc., 96 South Street, Hopkinton, MA, 01748. USA. This process will be processed in accordance with simplified acquisitions procedures as stated in FAR Part 13 13.106-1(b)(1) and is exempt for the requirements of FAR Part 6. The North American Industry Classification System code is 493110 and the business size standard is $25.5 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. The Division of Cancer Epidemiology and Genetics (DCEG) is a research program of the National Cancer Institute (NCI), one of the National Institutes of Health (NIH). The Division is the world's most comprehensive cancer epidemiology research group. Its renowned epidemiologists, geneticists, and biostatisticians conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Division's research impacts public health policy in the United States and around the world. NCI is conducting a study within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to evaluate the association between DNA methylation levels at chromosome 8q24 in peripheral blood and prostate cancer risk. The proposed contractor will carry out the laboratory analysis to measure DNA methylation using pyrosequencing. Next, the NCI Division of Cancer Epidemiology and Genetics previously contacted several companies to develop and validate targeted pyrosequencing assays to quantify DNA methylation levels at 8q24. However, only EpigenDx Inc was willing and able to provide services using the pyrosequencing method, which is a high-throughput, quantitative method that is considered highly reproducible and sensitive to quantify differences in DNA methylation between individuals. NCI proposes to continue to work with EpigenDx in the current proposed study because EpigenDx has already developed the needed pyrosequencing assays that NCI needs for this project, whereas if we were to work with another lab, then we would need to duplicate our previous pilot effort by re-developing the assays with the other lab and retesting assay validity and reproducibility before proceeding with the current study of DNA methylation at 8q24 and prostate cancer risk. We would also like to work with EpigenDx because EpigenDx has the capacity to complete the responsibilities requested within the timeframe specified and at a reasonable price. A sole source is intended for this order, based on the fact that EpigenDX has already developed pyrosequencing assays in previous pilot projects with NCI. In addition, it would be costly to duplicate, re-developing the assays with another lab and retesting assay validity and reproducibility. Lastly, EpigenDx is the only known vendor that has the capacity to complete the responsibilities of this project requested within the timeframe specified by NCI. This is not a solicitation for competitive quotations. However, if any interested party especially small business, believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on, July 28, 2014. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Gwennifer Epps, Contracting Officer at eppsg@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA), through sam.gov. No collect calls will be accepted. Please reference solicitation number N02CP42581-83 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP42581-83/listing.html)
- Place of Performance
- Address: The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03423163-W 20140714/140712233029-25707acdca47cc3115805b6e0c807f3f (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |